AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion A Randomized Multicenter Study
The purpose of this research study is to determine if the IMPEDE-FX RapidFill System is safe and helps to shrink abdominal aortic aneurysm (AAA) sacs after an endovascular stent graft has been placed.
AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3
This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Abdominal Core Health & Hernia Program | NYU Langone Health
NYU Langone’s Abdominal Core Health and Hernia Program provides simple and complex hernia repair and abdominal wall reconstruction.
Abdominal Core Health & Hernia Program Doctors | NYU Langone Health
Find a doctor at the Abdominal Core Health & Hernia Program at NYU Langone.
Ablation for Kidney Cancer | NYU Langone Health
NYU Langone doctors may use extreme cold or heat, called ablation, to destroy kidney cancer tumors.
Ablation Therapies for Liver Cancer & Liver Metastases | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may use heat therapy, called ablation, to manage liver cancer and liver metastases.
Ablation Therapy for Non-Small Cell Lung Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may recommend ablation therapies for people who have non-small cell lung cancer.
Ablation Treatment for Prostate Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may recommend minimally invasive ablation when treating prostate cancer patients.
Abnormal Pap Test Results | NYU Langone Health
Doctors at NYU Langone are experts in assessing Pap test results and determining if further testing or treatment is needed.
About Hassenfeld Children’s Hospital | NYU Langone Health
Hassenfeld Children’s Hospital at NYU Langone is home to more than 400 doctors representing more than 35 medical specialties.